Clinical Study
Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis
Table 2
B lymphoma patient characteristics.
| Sera analysis | | Responders
| Nonresponders
|
| Median age (years) | 56 (52–79) | 59 | Gender (M/F) | 7/1 | 2/3 | Histology | | | Diffuse large B cells | 7 | 1 | Indolent | 1 | 4 | Stage | | | I/II | 3 | 2 | III/IV | 5 | 3 | Treatment | | | Rituximab monotherapy | 5 | 1 | Rituximab chemotherapy | 3 | 4 |
|
|